S. O. WAIFE, M.D., F.A.C.P.; C. J. JANSEN JR., M.D.; R. E. CRABTREE, PH.D.; E. L. GRINNAN, PH.D.; P. J. FOUTS, M.D., F.A.C.P.
Since the discovery of vitamin B12 as the essential hematopoietic factor deficient in patients with pernicious anemia in relapse, there have been a number of studies using crystalline cyanocobalamin, without intrinsic factor, in oral therapy. Doses of less than 30 micrograms a day generally have been unsuccessful (1). Suboptimal responses have been reported on doses of up to 100 micrograms a day (1, 2). Better results have followed administration of still larger amounts—as much as 1,000 micrograms a day (3). Other schedules have been used, for example, 1,000 micrograms (1 milligram) once a week (3-7). In Table 1, we have
WAIFE SO, JANSEN CJ, CRABTREE RE, et al. Oral Vitamin B12 without Intrinsic Factor in the Treatment of Pernicious Anemia. Ann Intern Med. 1963;58:810–817. doi: 10.7326/0003-4819-58-5-810
Download citation file:
Published: Ann Intern Med. 1963;58(5):810-817.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use